All In Biotech

Drug Trial Radar · NCT03443414

Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.

Last checked: Nov 20, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

405

Actual

Start

Jun 1, 2017

Primary completion

Jan 23, 2018

Study completion Feb 7, 2018

Sponsor

Sponsor type
Industry
First posted
Feb 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.

Conditions

  • COPD

Interventions

  • RPL554 suspensionDrug

    A dual PDE3/PDE 4 inhibitor

  • PlaceboDrug

    Placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).

Locations

49 sites in 6 countries. Site status is shown where the registry gives one.

  • Clinic for pneumonology

    Pleven, Bulgaria

  • SHATPPD-Ruse EOOD

    Rousse, Bulgaria

  • Fifth MHAT - Sofia EAD

    Sofia, Bulgaria

  • MHAT 'Lyulin', EAD

    Sofia, Bulgaria

  • NMTH Tsar Boris III

    Sofia, Bulgaria

  • UMHAT 'Alexandrovska' EAD

    Sofia, Bulgaria

  • UMHAT 'Sveta Anna' AD

    Sofia, Bulgaria

  • Medical Center Nov

    Stara Zagora, Bulgaria

  • MediTrial s.r.o.

    Jindřichův Hradec, Czechia

  • Plicni stredisko Teplice

    Teplice, Czechia

  • Aerzte fuer Lungen- und

    Berlin, Germany

  • Charite Campus Mitte

    Berlin, Germany

  • emovis GmbH

    Berlin, Germany

  • Studienpraxis Berlin

    Berlin, Germany

  • IKF Pneumologie GmbH & Co. KG

    Frankfurt, Germany

  • Praxis Dr. Keller

    Frankfurt, Germany

  • Inamed GmbH

    Gauting, Germany

  • PRI Pulmonary Research

    Großhansdorf, Germany

  • Hamburger Institut fuer

    Hamburg, Germany

  • Gemeinschaftspraxis Dres

    Koblenz, Germany

  • POIS Leipzig GbR

    Leipzig, Germany

  • SALVUS UG Centre for Clinial Trials

    Leipzig, Germany

  • KLB Gesundheitsforschung

    Lübeck, Germany

  • Pneumologische Praxis Pasing

    München, Germany

  • Pneumologie Odeonsplatz

    Munich, Germany

  • Ballenberger Freytag Wenisch

    Neu-Isenburg, Germany

  • Dr. Christian Schlenska

    Peine, Germany

  • CERMED

    Bialystok, Poland

  • Indywidualna Specjalistyczna

    Bialystok, Poland

  • KLIMED Marek Klimkiewicz

    Bychawa, Poland

  • Silmedic sp. z o.o.

    Katowice, Poland

  • Grazyna Pulka Specjalistyczny

    Krakow, Poland

  • Malopolskie Centrum Alergologii

    Krakow, Poland

  • Centrum Terapii Wspólczesnej

    Lodz, Poland

  • Uniwersytecki Szpital Klin

    Lodz, Poland

  • NZOZ Alergo-MEDSpecjalistyczna

    Poznan, Poland

  • ETG Network Sp z o o

    Skierniewice, Poland

  • Centrum Medyczne Pratia

    Warsaw, Poland

  • Mazowieckie Centrum Medyczne

    Warsaw, Poland

  • Centrum Badan Klinicznych

    Wroclaw, Poland

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.